Controlling Hypertension Through Education and Coaching in Kidney Disease
Launched by UNIVERSITY OF MICHIGAN · Sep 10, 2019
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Patients that meet eligibility criteria and are seen in a clinic assigned to the control group will be given a Control-Encounter Decision Intervention (Control-EDI) about kidney disease in general (not tailored to the patient) by their primary care provider. Eligible patients that agree to participate and give consent will complete enrollment, 1, 6, and 12 month follow-up visits.
Eligible patients that are seen in a clinic assigned to the intervention group will be given a personalized Intervention-EDI by their primary care provider. Following this, eligible patients that agree to particip...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of CKD stage 3, 4, or 5 documented in medical record
- • Aware of CKD diagnosis
- • Has diagnosis of hypertension documented in medical record and most recent Blood Pressure (BP) within the last year meets criteria of uncontrolled hypertension (≥140 mmHg, and/or a diastolic blood pressure ≥90 mmHg noted in an ambulatory care setting within the past one year)
- • Estimated glomerular filtration rate (eGFR) of \<60 within the last 18 months documented in the medical record
- Exclusion Criteria:
- • Currently on dialysis permanently (i.e. are considered "end-stage renal disease" and receiving dialysis)
- • Previous kidney transplant
- • Pregnant (indicated by medical record or if patient self-identifies as pregnant)
- • Has cognitive, language, or vision impairment(s) that would prohibit participating in education, taking surveys, or participating in coaching activities
- • Has terminal illness
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Ann Arbor, Michigan, United States
Brighton, Michigan, United States
Chelsea, Michigan, United States
Detroit, Michigan, United States
Detroit, Michigan, United States
Dexter, Michigan, United States
Livonia, Michigan, United States
Northville, Michigan, United States
Ypsilanti, Michigan, United States
Canton, Michigan, United States
Patients applied
Trial Officials
Julie Wright, MD
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials